IOVA

6.9005.61%
ID

Iain D. Dukes

Independent Chairman of the Board

Dr. Iain D. Dukes, M.A. D.Phil. & Ph.D., serves as Chair of Scientific Advisory Board at Dogwood Therapeutics, Inc. since June 2026. He is the Chairman, Chief Business Officer & Executive Director of Brenig Therapeutics, Inc. Dr. Dukes is a Director of NeRRe Therapeutics Ltd. Dr. Dukes serves as President at Kartos Therapeutics, Inc. He is Secretary & Director of Traws Pharma, Inc. from April 15, 2025 and was Interim CEO from April 15, 2025 until October 1, 2025 and serves as Chief Executive Officer since October 1, 2025. He was Executive Chairman of Traws Pharma, Inc. from April 1, 2024 to April 15, 2025. He was Interim CEO & Executive Chairman of Traws Pharma, Inc. from March 31, 2025 to April 15, 2025. He has held leadership roles in public and private biopharmaceutical companies, leveraging vast experience in corporate, strategic and product development. He is biopharmaceutical professional with substantial experience in senior leadership roles in venture capital, business development and licensing, as well as drug discovery and development. He has served on the board of numerous public and private biopharma organizations. He is Member of Advisory Board of Militia Hill Ventures. He serves as Director at Kartos Therapeutics, Inc. He served as the Chairman & Venture Partner of OrbiMed Advisors LLC. He serves as Venture Partner at the firm since August 2016. He has been Chief Executive Officer of Viriom Inc. from February 2019 until December 2024. He serves as Executive Chairman at Angiex, Inc. since February 2020. He served as Chairman at Theseus Pharmaceuticals, Inc. since May 2021 until February 14, 2024 and is its Co-Founder. He served as Director of Theseus Pharmaceuticals, Inc. from June 2018 until April 2024. From June 2018 until April 23, 2021, he served as Chief Executive Officer of Theseus Pharmaceuticals, Inc. and from April 23, 2021 until September 2021, he served as its Executive Chairman. He served as Interim Chief Executive Officer, Board Chairman, Vice President, Treasurer and Secretary of Theseus Pharmaceuticals, Inc. He served as President of Theseus Pharmaceuticals, Inc. He is Independent Director at Feldan Bio Inc. (Feldan Therapeutics) since February 2021. He was an Independent Director to Supervisory Board at Themis Bioscience GmbH since January 2020 until June 2020. He serves as Director at ENYO Pharma SA since October 2019 he joined the firm in 2016. He served as the President and Chief Executive Officer at Essentialis, Inc. and Essentialis Therapeutics. He has been an Independent Director of Ikena Oncology, Inc. from November 2016 until July 2025. In September 2017, he co-founded Kartos Therapeutics, Inc. and serves as President. He also co-founded Telios Pharmaceuticals, Inc. where he serves as President. He served as Senior Vice President of Business Development and Licensing at Merck & Co. from August 2013 through May 2016 and oversaw all licensing deals at Merck Research Laboratories. He served as Vice President, Scientific and Technology Licensing at GlaxoSmithKline from 2000 to 2007. He was responsible for all business development activity for MSD Research Laboratories. Before joining MSD, he served as vice president of External Research and Development at Amgen Incorporated from August 2010 to August 2013. He previously also held the position of Vice President, Scientific and Technology Licensing at GlaxoSmithKline in addition to executive leadership roles and Board positions at several biotechnology companies.From 2000 to 2007, he was Vice President of Scientific and Technology Licensing at GlaxoSmithKline and prior to that, from 1990 to 1999, he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. He has experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership and as a consultant to numerous biotech and venture capital organizations. From October 2017 to July 2020, he was a board member and Chairman of KaNDy Therapeutics Ltd. He is Independent Chairman of the Board at Iovance Biotherapeutics, Inc. (formerly known as Lion Biotechnologies, Inc.) since August 16, 2016. He is a Director of ENYO Pharma. He served as Non-Executive Director of ReViral Ltd. until June 2022 and is Non-Executive Director since 2025. He serves as the Member of the Board of Directors at NeRRe Therapeutics Ltd. He has been independent Director of Iovance Biotherapeutics, Inc. (formerly known as Lion Biotechnologies, Inc.) since August 4, 2016. He served as Director of Ikena Oncology, Inc. since November 2016. He serves on the Board of Celyn Therapeutics and Gwynant Therapeutics since September 2021. He is co-founder and chairman of the Loch Group. He received BSc in Pharmacology from the University of Bath in 1976-1980 and MSc in Cardiovascular Studies from the University of Leeds in 1980-1981. He serves on the board of directors of Rathlin Therapeutics and Clywedog Therapeutics, Inc since August 2016. He obtained Doctor of Philosophy degree in Pharmacology and Physiology from Oxford University from 1981 to 1983 and MA in Jurisprudence (Law) from the University of Oxford in 1986-1989 and BA in Jurisprudence from the University of Oxford. He serves as Chief Executive Officer and Chairman of Eilean Therapeutics LLC since July 2022. He serves as President of Dinas Therapeutics, Inc. since March 2022. He served as Chairman of Lomond Therapeutics, Inc. from January 2020 until November 1, 2024 and serves as Chief Executive Officer and Chairman of its parent company, Lomond Therapeutics Holdings, Inc., since November 1, 2024. KaNDy Therapeutics Ltd. was acquired by Bayer AG in September 2020. Themis Bioscience GmbH was acquired by Merck & Co. in June 2020. ReViral Ltd. was acquired by Pfizer Inc. in June 2022. Theseus Pharmaceuticals, Inc. was acquired by Concentra Biosciences, LLC in April 2024.

公司職務